WT Wealth Management Has $492,000 Position in Eli Lilly and Company (NYSE:LLY)

by · The Cerbat Gem

WT Wealth Management raised its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 14.5% in the third quarter, HoldingsChannel.com reports. The fund owned 916 shares of the company’s stock after purchasing an additional 116 shares during the quarter. WT Wealth Management’s holdings in Eli Lilly and Company were worth $492,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in LLY. Thompson Investment Management Inc. bought a new position in shares of Eli Lilly and Company in the third quarter valued at about $27,000. Retirement Group LLC raised its position in shares of Eli Lilly and Company by 159.1% in the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after purchasing an additional 35 shares during the period. Cornerstone Planning Group LLC bought a new position in shares of Eli Lilly and Company in the second quarter valued at about $33,000. Legacy Financial Group LLC bought a new position in shares of Eli Lilly and Company in the third quarter valued at about $35,000. Finally, Optiver Holding B.V. bought a new position in Eli Lilly and Company during the third quarter worth about $36,000. Institutional investors and hedge funds own 81.38% of the company’s stock.

Insiders Place Their Bets

In related news, major shareholder Lilly Endowment Inc sold 34,538 shares of the business’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $631.81, for a total value of $21,821,453.78. Following the transaction, the insider now directly owns 99,719,884 shares of the company’s stock, valued at approximately $63,004,019,910.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold 195,055 shares of company stock valued at $125,254,657 in the last three months. 0.13% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on LLY shares. Bank of America raised their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Barclays increased their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 7th. BMO Capital Markets raised their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday. Finally, Truist Financial raised their price target on shares of Eli Lilly and Company from $650.00 to $850.00 and gave the company a “buy” rating in a research note on Wednesday, February 7th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $677.62.

Read Our Latest Research Report on Eli Lilly and Company

Eli Lilly and Company Stock Up 2.7 %

LLY stock traded up $19.52 during midday trading on Tuesday, reaching $753.89. 1,826,201 shares of the company’s stock traded hands, compared to its average volume of 3,391,942. The company has a market cap of $716.32 billion, a price-to-earnings ratio of 129.59, a P/E/G ratio of 1.67 and a beta of 0.34. The firm’s fifty day moving average price is $697.02 and its 200-day moving average price is $620.01. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 52 week low of $317.24 and a 52 week high of $800.78.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.09 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 12.44 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Articles

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).